Key result
Women with STEMI were significantly less likely than men to receive reperfusion therapy in the 2004-2006 period (64% vs 75%; OR 0.80, 95% CI 0.73-0.89, p<0.001) and had higher inhospital mortality.
Why the study?
Does female gender remain associated with lower use of evidence-based therapies and worse outcomes in STEMI patients over time?
Cohort (n=30,077)
Yes
Does female gender remain associated with lower use of evidence-based therapies and worse outcomes in STEMI patients over time?
Odds Ratio: 0.8 (95% CI 0.73–0.89)
Absolute Event Rate: 64% vs 75%
p-value: p=<0.001
Gender disparities in STEMI management and inhospital mortality persisted over a decade despite the transition to primary PCI as the preferred reperfusion strategy.
Women with STEMI still receive less reperfusion than men in the pPCI era; leaves open whether targeted strategies can close persistent gaps.
OBJECTIVE: In ST elevation myocardial infarction women received less evidence-based medicine and had worse outcome during the fibrinolytic era. With the shift to primary percutaneous coronary intervention (pPCI) as preferred reperfusion strategy, the authors aimed to investigate whether these gender differences has diminished. DESIGN, SETTING AND PARTICIPANTS: Cohort study including consecutive ST elevation myocardial infarction patients registered 1998-2000 (n=15 697) and 2004-2006 (n=14 380) in the Register of Information and Knowledge about Swedish Heart Intensive care Admissions. OUTCOME MEASURES: 1. Use of evidence-based medicine such as reperfusion therapy (pPCI or fibrinolysis) and evidence-based drugs at discharge. 2. Inhospital and 1-year mortality. RESULTS: Of those who got reperfusion therapy, pPCI was the choice in 9% in the early period compared with 68% in the late period. In the early period, reperfusion therapy was given to 63% of women versus 71% of men, p<0.001. Corresponding figures in the late period were 64% vs 75%, p<0.001. After multivariable adjustments, the ORs (women vs men) were 0.86 (95% CI 0.78 to 0.94) in the early and 0.80 (95% CI 0.73 to 0.89) in the late period. As regards evidence-based secondary preventive drugs at discharge in hospital survivors (platelet inhibitors, statins, ACE inhibitors/angiotensin receptor blockers and β-blockers), there were small gender differences in the early period. In the late period, women had 14%-25% less chance of receiving these drugs, OR 0.75 (95% CI 0.68 to 0.81) through 0.86 (95% CI 0.73 to 1.00). In both periods, multivariable-adjusted inhospital mortality was higher in women, OR 1.18 (95% CI 1.02 to 1.36) and 1.21 (1.00 to 1.46). One-year mortality was gender equal, HR 0.95 (95% CI 0.87 to 1.05) and 0.96 (0.86 to 1.08), after adding evidence-based medicine to the multivariable adjustments. CONCLUSION: In spite of an intense gender debate, focus on guideline adherence and the change in reperfusion strategy, the last decade gender differences in use of reperfusion therapy and evidence-based therapy at discharge did not decline during the study period, rather the opposite. Moreover, higher mortality in women persisted.
No takes yet. Share an insight, caveat, or question.
Lawesson et al. (2012) conducted a cohort in ST elevation myocardial infarction (n=30,077). Female sex vs. Male sex was evaluated on Use of reperfusion therapy (late period 2004-2006) (OR 0.80, 95% CI 0.73-0.89, p=<0.001). Women with STEMI were significantly less likely than men to receive reperfusion therapy in the 2004-2006 period (64% vs 75%; OR 0.80, 95% CI 0.73-0.89, p<0.001) and had higher inhospital mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: